Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha-galactosylceramide: potential immunomodulatory activity and future application.

Yoshihiro Hayakawa1, Dale I Godfrey, Mark J Smyth

  • 1Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Victoria 3002, Australia.

Current Medicinal Chemistry
|February 3, 2004
PubMed
Summary

Alpha-galactosylceramide (alpha-GalCer) activates invariant NKT cells, crucial for immune responses and autoimmune disease suppression. This review explores alpha-GalCer

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conserved T cell receptor usage underpins recognition of CD1c presenting a mycobacterial lipid.

bioRxiv : the preprint server for biology·2026
Same author

Specific targeting of MR1-antigen complexes using nanobodies.

bioRxiv : the preprint server for biology·2026
Same author

The NF-κB transcription factor RelA directs mucosal-associated invariant T-cell development.

Immunology and cell biology·2026
Same author

Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59.

NPJ vaccines·2026
Same author

Sideways lipid presentation by the antigen-presenting molecule CD1c.

Nature communications·2025
Same author

Sideways lipid presentation by the antigen-presenting molecule CD1c.

bioRxiv : the preprint server for biology·2025

Area of Science:

  • Immunology
  • Glycolipid research
  • T cell activation

Background:

  • Alpha-galactosylceramide (alpha-GalCer) is a glycolipid recognized by invariant natural killer T (iNKT) cells.
  • iNKT cells are a unique T cell subset with potent immunoregulatory functions.

Purpose of the Study:

  • To review the immunomodulatory activity of alpha-GalCer.
  • To discuss the potential clinical applications of alpha-GalCer in human studies.

Main Methods:

  • Review of recent studies on alpha-GalCer-induced iNKT cell activation.
  • Analysis of mechanisms in immune responses to tumors and microbes.
  • Evaluation of alpha-GalCer's role in autoimmune disease suppression.

Main Results:

Related Experiment Videos

  • Alpha-GalCer powerfully activates iNKT cells to produce key cytokines like interferon-gamma and IL-4.
  • This activation influences various immune cells and contributes to anti-tumor and anti-microbial immunity.
  • Alpha-GalCer demonstrates potential in suppressing autoimmune diseases.

Conclusions:

  • Alpha-GalCer exhibits significant immunomodulatory potential.
  • Further clinical studies are warranted to explore its therapeutic applications in humans.